methyl L-α-benzyloxyisocaproate | 108061-34-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl L-α-benzyloxyisocaproate
• 英文别名: (S)-methyl 2-benzyloxy-4-methylpentanoate；methyl (S)-2-phenylmethoxy-4-methylvalerate；methyl (2S)-2-benzoxy-4-methylpentanoate；methyl(2S)-2-benzoxy-4-methylpentanoate；methyl (2S)-4-methyl-2-phenylmethoxypentanoate
• CAS: 108061-34-3
• 化学式: C₁₄H₂₀O₃
• 分子量: 236.311
• InChiKey: BLVMTKJTPHJSPE-ZDUSSCGKSA-N

物化性质

• 沸点：
  321.9±17.0 °C(Predicted)
• 密度：
  1.019±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl L-α-benzyloxyisocaproate 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 methyl N-<2(S)-benzyloxy-4-methylpentyl>glycyl-L-valyl-L-phenylalaninate
  参考文献：
  名称：

  N-[2(S)-hydroxy-4-methylpentyl] tripeptide derivatives as inhibitors of renin

  摘要：

  DOI：

  10.1016/0223-5234(88)90171-7
• 作为产物：
  描述：

  L-alpha-羟基异己酸 在 silver(l) oxide 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 methyl L-α-benzyloxyisocaproate
  参考文献：
  名称：

  N-[2(S)-hydroxy-4-methylpentyl] tripeptide derivatives as inhibitors of renin

  摘要：

  DOI：

  10.1016/0223-5234(88)90171-7

文献信息

• A Brønsted Acid Catalyzed Cascade Reaction for the Conversion of Indoles to α‐(3‐Indolyl) Ketones by Using 2‐Benzyloxy Aldehydes
  作者：Ankush Banerjee、Modhu Sudan Maji

  DOI：10.1002/chem.201902268

  日期：2019.9.2

  A Brønsted acid catalyzed, operationally simple, scalable route to several functionalized α-(3-indolyl) ketones has been developed and the long-standing regioisomeric issue has been eliminated by choosing appropriate carbonyls. A readily available and cheap bottle reagent was used as the catalyst. This protocol was also applicable to the synthesis of densely functionalized α-(3-pyrrolyl) ketones. A

  已经开发出布朗斯台德酸催化的，操作简单的，可扩展的途径，以合成多种官能化的α-（3-吲哚基）酮，并且通过选择合适的羰基化合物消除了长期存在的区域异构问题。使用容易获得且便宜的瓶试剂作为催化剂。该方案也适用于高密度官能化的α-（3-吡咯基）酮的合成。详细的机理研究证实烯醇醚作为反应中间体。几种后合成修饰以及易于获得的β-咔啉，色胺，色胺醇和螺吲哚烯碱都证明了这种功能强大的构件的合成效用。基于这一概念，通过级联环化策略构建了功能化的咔唑。
• Peptide, peptide analog and amino acid analog protease inhibitors
  申请人：SIBIA Neurosciences, Inc.

  公开号：US05969100A1

  公开（公告）日：1999-10-19

  Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae (I), (II) and (III): ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, norleucine; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.B is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is an alcohol, particularly a secondary alcohol.

  提供了用于治疗以脑部淀粉样沉积为特征的疾病的化合物的使用方法和化合物。在这些化合物中，其中包括式(I)、(II)和(III)的化合物：##STR1## 其中R.sub.1 最好是2-甲基丙烯、2-丁烯、正亮氨酸；R.sub.2、R.sub.4 和 R.sub.8 分别独立为甲基或乙基；R.sub.3 最好是异丁基或苯基；R.sub.5 最好是异丁基；R.sub.6 为H或甲基；R.sub.7 --(Q).sub.n 最好是苄氧羰基或乙酰基；Q 最好是 --C(O)--；R.sub.B 最好是异丁基；R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1，其中T 最好是氧或碳，D 最好是一种单不饱和的C.sub.3-4 烯烃，更好的是；X 是一种醇，特别是二级醇。
• Peptide and peptide analog protease inhibitors
  申请人：SIBIA Neurosciences, Inc.

  公开号：US05714471A1

  公开（公告）日：1998-02-03

  Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide.

  提供了用于治疗以脑部淀粉样沉积为特征的疾病的化合物和化合物的使用方法。其中包括具有以下式I和II的化合物：##STR1## 在其中R.sub.1最好是2-甲基丙烯、2-丁烯、环己基或环己基甲基；R.sub.2、R.sub.4和R.sub.8各自独立地是甲基或乙基；R.sub.3最好是异丁基或苯基；R.sub.5最好是异丁基；R.sub.6是H或甲基；R.sub.7--(Q).sub.n最好是苄氧羰基或乙酰基；Q最好是--C(O)--；R.sub.8最好是异丁基；R.sub.A=--(T).sub.m--(D).sub.m--R.sub.1，其中T最好是氧或碳，D最好是一种单不饱和的C.sub.3-4烯烃，更好的是；X最好是α-酮酯或α-酮酰胺。
• Total Syntheses and Configuration Assignments of JBIR-06 and Related Depsipeptides
  作者：Chie Hamada、Yoshinosuke Usuki、Daiki Takeuchi、Hikaru Ogawa、Ryota Abe、Tetsuya Satoh

  DOI：10.1021/acs.orglett.8b03944

  日期：2019.2.15

  The first total syntheses of JBIR-06 and two analogous depsipeptides, 12-membered antimycin-class antibiotics, have been accomplished via Shiina macrolactonization. Comparison of the spectroscopic data of the synthesized compounds with those reported for natural products verified that the absolute configutation of the natural products was (2S,4S,6S,7R,14S).

  JBIR-06和两种类似的二肽，十二元抗霉素类抗生素的第一批总合成已通过椎名大内酯化法完成。将合成化合物的光谱数据与天然产物报道的光谱数据进行比较，证实了天然产物的绝对构型为（2 S，4 S，6 S，7 R，14 S）。
• Methods of treating neurodegenerative disorders using protease inhibitors
  申请人：SIBIA Neurosciences Inc.

  公开号：US06051684A1

  公开（公告）日：2000-04-18

  Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R.sub.1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each preferably independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is preferably H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; and X is preferably an aldehyde, .alpha.-ketoester or .alpha.-ketoamide.

  提供了用于治疗由淀粉样物质脑沉积所表征的疾病的化合物使用方法。提供的化合物中，用于该方法的化合物包括以下结构式：##STR1##在该结构式中，R.sub.1最好是2-甲基丙烯基、2-丁烯基、环己基或环己基甲基；R.sub.2、R.sub.4和R.sub.8最好分别独立地是甲基或乙基；R.sub.3最好是异丁基或苯基；R.sub.5最好是异丁基；R.sub.6最好是H或甲基；R.sub.7--(Q).sub.n最好是苄氧羰基或乙酰基；Q最好是--C(O)--；X最好是醛、α-酮酸酯或α-酮酰胺。